m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG01799)
Name |
Methotrexate gamma-hydroxamic acid
|
||||
---|---|---|---|---|---|
Synonyms |
methotrexate gamma-hydroxamic acid; CHEMBL244883
Click to Show/Hide
|
||||
Status |
Investigative
|
||||
Structure |
|
||||
Formula |
C20H23N9O5
|
||||
InChI |
1S/C20H23N9O5/c1-29(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(30)28-34/h2-5,8,13,34H,6-7,9H2,1H3,(H,25,31)(H,28,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1
|
||||
InChIKey |
YUQBNZUBNMWBAQ-ZDUSSCGKSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Matrix metalloproteinase-2 (MMP-2)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [1], [2] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Matrix metalloproteinase-2 (MMP-2) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-2 (MMP-2). | [2], [3] | ||
Matrix metalloproteinase-9 (MMP-9)
E3 ubiquitin-protein ligase Hakai (CBLL1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The E3 ubiquitin-protein ligase Hakai (CBLL1) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [1], [4] | ||
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Matrix metalloproteinase-9 (MMP-9) is a therapeutic target for Methotrexate gamma-hydroxamic acid. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Methotrexate gamma-hydroxamic acid through regulating the expression of Matrix metalloproteinase-9 (MMP-9). | [4], [5] | ||
References